Is Your Comparator Strategy Delaying Your Clinical Trial?

Comparator sourcing plays a defining role in the success of global clinical trials—yet it is often misunderstood as a simple procurement activity rather than a strategic function.

At the recent GCSG Seoul conference, Roberta Blaj shared the realities behind comparator strategy and why early, deliberate planning is critical to avoiding costly delays.

For biopharmaceutical companies, comparator sourcing is not just about securing supply—it is about managing a complex balance of regulatory requirements, financial exposure, operational timelines, and clinical considerations. As highlighted throughout the flipbook, decisions made early in the process directly shape trial outcomes.

From defining what a comparator truly represents within the IMP framework, to understanding the trade-offs between price, speed, and quality, the message is clear: there is no single sourcing model that fits every trial. Success comes from designing a strategy that aligns with constraints, mitigates risk, and maintains control across global markets.

Supporting stronger clinical trial strategies

At Tanner Pharma, our Clinical Trial Solutions are built to simplify comparator sourcing through reliable, GxP-compliant logistics, global clinical trial support, and proactive risk mitigation. If you are evaluating your comparator strategy or planning an upcoming study, our team is here to help you stay on track and on time.